New eczema drug shows promise in Mid-Stage trial
NCT ID NCT07399067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive either the drug or a placebo, and researchers will monitor side effects and how well the drug works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100192, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common antibiotic boost eczema treatment?
- New biologic drug aims to clear stubborn eczema in just 24 weeks
- Skin disease evolution under the microscope: a 17-Year look at what drives severity
- Could a simple body wash and cream soothe eczema without a prescription?
- Skin sodium levels may hold clues to eczema in older adults
- Could a daily powder boost skin elasticity and fight fatigue?